|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the MRVL 10-K filed Jul 2, 2007. Termination-related charges: With respect to option grants to an
employee, the post-service exercise period for 605,332 vested stock options was
effectively extended by an unpaid leave of absence arrangement which appears to
have lacked substance. The Company applied APB 25 as if the leave of
absence arrangement was a constructive modification extending the exercise
period of vested awards. The Company recorded $10.0 million in additional
deferred compensation charges in fiscal 2001.
Notwithstanding the foregoing, the lack of conclusive evidence in the case of certain grants required management to apply significant judgment in establishing revised measurement dates. The Company determined that the total cumulative, pre-tax, non-cash, stock-based compensation expense resulting from 111 MARVELL TECHNOLOGY GROUP LTD. revised measurement dates under APB 25 was $327.4 million for periods through fiscal 2006. There was no impact on revenue. The Company adopted SFAS 123R at the beginning of fiscal 2007. As a result of the above adjustments, and after revisions to the SFAS 123R fair value assumptions, the pre-tax, non-cash, stock-based compensation expense in the first quarter of fiscal 2007 increased by $4.2 million to $48.8 million. This excerpt taken from the MRVL 10-Q filed Jul 2, 2007. Termination-related charges: With respect to option grants to an employee, the
post-service exercise period for 605,332 vested stock options was effectively
extended by an unpaid leave of absence arrangement which appears to have lacked
substance. We applied APB 25 as if
the leave of absence arrangement was a constructive modification extending the
exercise period of vested awards. We recorded $10.0 million in additional
deferred compensation charges in fiscal 2001.
Notwithstanding the foregoing, the lack of conclusive evidence in the case of certain grants required our management to apply significant judgment in establishing revised measurement dates. We determined that the total cumulative, pre-tax, non-cash, stock-based compensation expense resulting from revised measurement dates under APB 25 was $327.4 million for periods through fiscal 2006. There was no impact on revenue. We adopted SFAS 123R at the beginning of fiscal 2007. This excerpt taken from the MRVL 10-Q filed Jul 2, 2007. Termination-related charges: With respect to option grants to an employee, the
post-service exercise period for 605,332 vested stock options was effectively
extended by an unpaid leave of absence arrangement which appears to have lacked
substance. We applied APB 25 as if
the leave of absence arrangement was a constructive modification extending the
exercise period of vested awards. We recorded $10.0 million in additional
deferred compensation charges in fiscal 2001.
Notwithstanding the foregoing, the lack of conclusive evidence in the case of certain grants required our management to apply significant judgment in establishing revised measurement dates. We determined that the total cumulative, pre-tax, non-cash, stock-based compensation expense resulting from revised measurement dates under APB 25 was $327.4 million for periods through fiscal 2006. There was no impact on revenue. We adopted SFAS 123R at the beginning of fiscal 2007. As a result of the above adjustments, and after revisions to the SFAS 123R fair value assumptions, the pre-tax, non-cash, stock-based compensation expense in the first quarter of fiscal 2007 increased by $4.2 million to $48.8 million. This excerpt taken from the MRVL 10-Q filed Jul 2, 2007. Termination-related charges: With respect to option grants to an employee, the
post-service exercise period for 605,332 vested stock options was effectively
extended by an unpaid leave of absence arrangement which appears to have lacked
substance. We applied APB 25 as if
the leave of absence arrangement was a constructive modification extending the
exercise period of vested awards. We recorded $10.0 million in additional
deferred compensation charges in fiscal 2001.
Notwithstanding the foregoing, the lack of conclusive evidence in the case of certain grants required our management to apply significant judgment in establishing revised measurement dates. We determined that the total cumulative, pre-tax, non-cash, stock-based compensation expense resulting from revised measurement dates under APB 25 was $327.4 million for periods through fiscal 2006. There was no impact on revenue. We adopted SFAS 123R at the beginning of fiscal 2007. 45 | EXCERPTS ON THIS PAGE:
RELATED TOPICS for MRVL: |
| |||||||
